By STEVEN ZECOLA
Recursion Prescribed drugs introduced outcomes immediately for one its AI-discovered remedies. I used to be happy to see the big, sustained discount in polyps attributable to its remedy for Familial Adenomatous Polyposis. Recursions’ oral remedy might be seen by the normal scientific and regulatory neighborhood as “promising”.
Alternatively, I used to be disenchanted to not see/hear any reference to the financial savings of the price to society from this remedy and a imprecise reference to working with the FDA in 1H2026. Fairly frankly, the urgency appeared to be missing.
At present, treating FAP is an costly, lifelong endeavor for the 50,000+ survivors. Early detection methods value $10k+ and late detection $37k+. The associated fee to treating metastatic colorectal most cancers (for which FAP predisposes) could be extraordinarily excessive, as much as $300,000. General, the price to society from FAP simply exceeds $1 billion per 12 months, or greater than $15 billion on a gift worth foundation.
This remedy shouldn’t be topic to any additional regulatory delay. There may be sufficient info now on efficacy and security to have Recursion extra ahead with a broad software of this remedy, whereas persevering with check dosage ranges and stratifying the affected person inhabitants. The choice is extra unnecessary value and struggling.
Steve Zecola offered his internet software and internet hosting enterprise when he was identified with Parkinson’s illness twenty three years in the past. Since then, he has run a consulting follow, taught in graduate enterprise faculty, and exercised extensively
